Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Balchem Corporation is managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners and 2 distinct art units. This distribution shows that the company's current pending matters are being reviewed by different examiners in different specialized units, requiring a tailored approach for each filing. This structure indicates that the company's biotechnology interests are spread across multiple technical divisions.
BAZARGANI, ARYA AHMADI is the busiest examiner, managing 1 pending office action. With 2 total pending actions, the workload is split between the 2 distinct examiners. The company must address the specific requirements and historical tendencies of two different examiners across the biotechnology sector. For the practitioner, this requires managing two separate prosecution tracks while maintaining a consistent technical strategy within the Biotechnology & Pharmaceuticals technology area. No single examiner or art unit dominates the current pending portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BAZARGANI, ARYA AHMADI | 1 | 62.5% | +31.3% |
| LEE, WILLIAM Y | 1 | 48.0% | +34.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19078536 | COMPOSITIONS FOR THE CONTROLLED-RELEASE OF CHOLINE | BAZARGANI, ARYA AHMADI | — |
| 16694590 | METAL COMPLEX OR METAL CHELATE COMPOSITIONS COMPRISING MINIMAL NANOPARTICLES | LEE, WILLIAM Y | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19078536 | COMPOSITIONS FOR THE CONTROLLED-RELEASE OF CHOLINE | BAZARGANI, ARYA AHMADI | — |
| 16694590 | METAL COMPLEX OR METAL CHELATE COMPOSITIONS COMPRISING MINIMAL NANOPARTICLES | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19078536 | COMPOSITIONS FOR THE CONTROLLED-RELEASE OF CHOLINE | BAZARGANI, ARYA AHMADI | 1613 | §103§112 | Non-Final OA | — | Pending | Mar 13, 2025 |
| 16694590 | METAL COMPLEX OR METAL CHELATE COMPOSITIONS COMPRISING MINIMAL NANOPARTICLES | LEE, WILLIAM Y | 1623 | §103§112 | Final Rejection | — | Pending | Nov 25, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBalchem Corporation has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Arya Ahmadi Bazargani has the most, with 1 of Balchem Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
